Kaplan Matthew L.

Kaplan Matthew L., Director, accounts for 2 disclosed filings worth $64.2K, all concentrated in Nuvectis Pharma, Inc. (NVCT), active 2025–2026. The record is heavily weighted toward buying, with $64.2K in purchases against $0 in sales. The largest single open-market purchase on record is $64.2K in Nuvectis Pharma, Inc.. Data is sourced from official SEC Form 3, 4, and 5 filings.